Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 1/3/2026

Mupirocin Intranasal Ointment for Decolonization

Standard Application Protocol

  • Apply 2% mupirocin ointment into each nostril twice daily for 5-7 days to effectively decolonize Staphylococcus aureus nasal carriage and reduce infection risk 1, 2
  • Total treatment duration: 5-7 days for optimal decolonization 1, 2

Clinical Context-Specific Protocols

  • Start mupirocin application at least 48 hours before surgery and continue for 5-7 days total to decrease postoperative infections, reducing Staphylococcus aureus infectious complications by 45% (RR 0.55, 95% CI 0.34-0.89) compared to placebo 1, 2, 3
  • Combine mupirocin with twice-daily chlorhexidine mouthwash and daily chlorhexidine showers for comprehensive decolonization, significantly reducing nasal MRSA carriage (RR 0.63, 95% CI 0.52-0.75) 1, 2, 3, 4
  • For immunocompetent patients with recurrent staphylococcal skin infections, apply a 5-day course of mupirocin every month, reducing positive nasal cultures by 73% and skin infections by 58% over one year 5, 6

Important Clinical Considerations

  • No emergence of multidrug-resistant bacteria has been observed due to decolonization selection pressure 1, 7
  • Routine decolonization without prior microbiological screening is more cost-effective and provides better risk reduction than selective treatment, according to the American College of Surgeons 1, 7

Intranasal Mupirocin for Surgical Decolonization and Resistance Considerations

Preoperative Decolonization Efficacy

  • Initiating a 5‑ to 7‑day course of intranasal mupirocin 2% at least 48 hours before surgery reduces postoperative Staphylococcus aureus infections by 45 % (relative risk 0.55; 95 % CI 0.34–0.89). 8
  • Adding daily chlorhexidine body washes and twice‑daily chlorhexidine mouthwash to the mupirocin regimen further lowers MRSA carriage by 37 % (relative risk 0.63; 95 % CI 0.52–0.75). 8

Resistance Development Concerns

  • The CDC guidelines state that routine intranasal mupirocin use leads to rapid development of resistance in both S. aureus and coagulase‑negative staphylococci. 9
  • A separate CDC recommendation echoes the same finding, emphasizing the need for careful, targeted application of mupirocin to mitigate resistance emergence. 10